Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators

Aim: To develop a comprehensive item library of patient-reported, immunotherapy-related adverse events (irAEs) that draws from and expands on the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System. Methods: Literature review and iterative expert input. Based on a literature review of irAEs, we developed a framework of immunotherapy classes and their associated symptoms. Clinical experts then reviewed iterations of symptom summaries and item maps linked to the immunotherapy framework. Experts provided content review and feedback was shared across experts until consensus was reached. The iterative process facilitated creation of a Primary Symptom List associated with immune checkpoint modulators (ICMs), drawn from the larger set of symptoms. Existing FACIT items were mapped to the symptom list, and new items were written as needed to create the item library. Results: The full item library of irAEs is comprised of 239 items, covering 142 unique symptoms across 75 inflammatory reactions/immune conditions. A subset of 66 items comprises a Primary Symptom List considered most common/relevant to ICM treatment. This includes gastrointestinal, skin, pulmonary, neurologic, musculoskeletal, and multiple miscellaneous and constitutional symptoms. Conclusion: The FACIT Immunotherapy Item Library is a compilation of 239 self-report items that capture the wide range of AEs experienced by people receiving immune treatments. A subset of 66 items comprises a Primary Symptom List meant for ICM therapy. Use of items selected from this library is encouraged in clinical research and clinical practice evaluation.

[1]  D. Gerber,et al.  Autoimmunity, Checkpoint Inhibitor Therapy and Immune-related Adverse Events: A Review. , 2020, Seminars in cancer biology.

[2]  A. Oza,et al.  Development of the functional assessment of cancer therapy-immune checkpoint modulator (FACT-ICM): A scale to measure quality of life in cancer patients treated with ICMs , 2019, Annals of Oncology.

[3]  M. Janda,et al.  An outreach telephone program for advanced melanoma supportive care: Acceptability and feasibility. , 2019, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[4]  M. Ebert,et al.  Management of immune related adverse events induced by immune checkpoint inhibition. , 2019, Cancer letters.

[5]  L. Schapira,et al.  Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review. , 2019, Journal of pain and symptom management.

[6]  M. Levitt,et al.  Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study , 2019, Journal of clinical medicine research.

[7]  L. Howie,et al.  Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions , 2019, Clinical trials.

[8]  Matthew J. Frigault,et al.  Management of Immunotherapy-Related Toxicities, Version 1.2019. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  H. Jim,et al.  Patient reported toxicities: Development and validation of patient-reported symptom measure for lung cancer patients receiving immunotherapy. , 2019, Journal of Clinical Oncology.

[10]  J. Paty,et al.  Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. , 2019, The Lancet. Oncology.

[11]  Mark P. MacEachern,et al.  Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports , 2019, Clinical Diabetes and Endocrinology.

[12]  M. Lacouture,et al.  Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails , 2018, American Journal of Clinical Dermatology.

[13]  Claire Wang,et al.  Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians. , 2018, The Journal of emergency medicine.

[14]  G. Myers Immune-related adverse events of immune checkpoint inhibitors: a brief review. , 2018, Current oncology.

[15]  A. Gabrielli,et al.  Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature , 2018, Current drug safety.

[16]  A. Palumbo,et al.  Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study , 2018, Annals of Hematology.

[17]  A. Tai,et al.  Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis , 2018, Clinical and Translational Gastroenterology.

[18]  Laura C. Cappelli,et al.  Rheumatic immune-related adverse events from cancer immunotherapy , 2018, Nature Reviews Rheumatology.

[19]  M. Hara,et al.  Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease , 2018, Annals of Internal Medicine.

[20]  M. Atkins,et al.  The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management , 2018, JNCI cancer spectrum.

[21]  V. Sibaud Dermatologic Reactions to Immune Checkpoint Inhibitors , 2018, American Journal of Clinical Dermatology.

[22]  D. Cella,et al.  Cancer symptom response as an oncology clinical trial end point , 2018, Expert review of quality of life in cancer care.

[23]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[24]  L. Kottschade Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors , 2018, Current Oncology Reports.

[25]  L. Shen,et al.  Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors , 2018, Chronic diseases and translational medicine.

[26]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Motzer,et al.  Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Sullivan,et al.  Keeping Expectations in Check With Immune Checkpoint Inhibitors. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  G. De Velasco,et al.  Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials , 2018, Oncotarget.

[30]  Matthew D. Hellmann,et al.  Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.

[31]  M. Suarez‐Almazor,et al.  Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group , 2017, Journal of Immunotherapy for Cancer.

[32]  V. Anagnostou,et al.  Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity , 2017, Clinical Cancer Research.

[33]  N. Girard,et al.  Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients , 2017, European Respiratory Journal.

[34]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  C. L. Ventola,et al.  Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations. , 2017, P & T : a peer-reviewed journal for formulary management.

[36]  M. Suarez‐Almazor,et al.  Review: Immune‐Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer , 2017, Arthritis & rheumatology.

[37]  H. McLeod,et al.  American Society of Clinical Oncology Value Framework: Importance of Accurate Toxicity Data. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  E. Basch,et al.  Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting , 2017, Journal of Cancer Research and Clinical Oncology.

[39]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[40]  Ami A. Shah,et al.  Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab , 2016, Annals of the rheumatic diseases.

[41]  J. Soria,et al.  Immune-related adverse events with immune checkpoint blockade: a comprehensive review. , 2016, European journal of cancer.

[42]  K. Lohr,et al.  Patient-Reported Outcomes in Performance Measurement , 2015 .

[43]  A. Razak,et al.  A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  D. Cella,et al.  Re-personalizing precision medicine: is there a role for patient-reported outcomes? , 2015 .

[45]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Amy P Abernethy,et al.  Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). , 2014, Journal of the National Cancer Institute.

[47]  F. Hasson,et al.  The Delphi Technique in Nursing and Health Research , 2011 .

[48]  Daniel J Buysse,et al.  The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. , 2010, Journal of clinical epidemiology.

[49]  Alexia Iasonos,et al.  Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. , 2009, Journal of the National Cancer Institute.

[50]  David Artz,et al.  Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  U. S. Department of Health and Human Services FDA Cen Research,et al.  Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance , 2006, Health and quality of life outcomes.

[52]  David Cella,et al.  A Comprehensive Method for the Translation and Cross-Cultural Validation of Health Status Questionnaires , 2005, Evaluation & the health professions.

[53]  David Cella,et al.  The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation , 2003, Health and quality of life outcomes.

[54]  J. Crisp,et al.  The Delphi method? , 1997, Nursing research.

[55]  D. Cella,et al.  Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system , 1996, Quality of Life Research.

[56]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[57]  C. Robert,et al.  Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. , 2019, The Lancet. Haematology.